Gene Holdings Inc. remains a Buy, driven by promising LEGEND trial data for detalimogene voraplasmid. Learn more about ENGN stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback